These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 11450504

  • 21. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
    Landstedt-Hallin L, Adamson U, Lins PE.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3140-5. PubMed ID: 10487677
    [Abstract] [Full Text] [Related]

  • 22. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M, Laichuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H, Lavynenko O, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M.
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [Abstract] [Full Text] [Related]

  • 23. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 24. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
    Donatelli M, Sinagra D, Russo V, Bucalo ML, Giardina E, Cerasola GA, Bompiani G.
    Pharmatherapeutica; 1985 Jan; 4(2):69-75. PubMed ID: 3903780
    [Abstract] [Full Text] [Related]

  • 25. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P, Kattah W.
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [Abstract] [Full Text] [Related]

  • 26. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Saberi M, Ramazani Z, Rashidi H, Saberi A.
    Vasc Health Risk Manag; 2020 Oct; 16():241-248. PubMed ID: 32606720
    [Abstract] [Full Text] [Related]

  • 27. The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.
    Batch J, Ma A, Bird D, Noble R, Charles B, Ravenscroft P, Cameron D.
    Eur J Clin Pharmacol; 1990 Oct; 38(5):465-7. PubMed ID: 2199202
    [Abstract] [Full Text] [Related]

  • 28. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR.
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [Abstract] [Full Text] [Related]

  • 29. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD.
    J Diabetes Complications; 1994 May; 8(4):201-3. PubMed ID: 7833494
    [Abstract] [Full Text] [Related]

  • 30. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes.
    Ali AM, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M.
    Diabetes Care; 2020 Jun; 43(6):1234-1241. PubMed ID: 32220916
    [Abstract] [Full Text] [Related]

  • 31. Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
    Wajchenberg BL, Santomauro AT, Giannella-Neto D, Borghi VC, Porrelli RN.
    Diabetes Res Clin Pract; 1992 Aug; 17(2):89-97. PubMed ID: 1425152
    [Abstract] [Full Text] [Related]

  • 32. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Aug; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 33. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Güvener N, Gedik O.
    Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
    [Abstract] [Full Text] [Related]

  • 34. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 35. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 36. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 37. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J, Levy JC, Barrow BA, Manley SE, Turner RC.
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [Abstract] [Full Text] [Related]

  • 38. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS, Heine RJ.
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [Abstract] [Full Text] [Related]

  • 39. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.
    Drouin P.
    J Diabetes Complications; 2000 May; 14(4):185-91. PubMed ID: 11004426
    [Abstract] [Full Text] [Related]

  • 40. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
    Wu CZ, Pei D, Hsieh AT, Wang K, Lin JD, Lee LH, Chu YM, Hsiao FC, Pei C, Hsia TL.
    Arch Pharm Res; 2010 Mar; 33(3):411-6. PubMed ID: 20361306
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.